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Background:  Thymidylate synthase (TS) catalyzes the reductive methylation of
deoxyuridine monophosphate (dUMP) by 5,10-methylenetetrahydrofolate
(CH2H4folate) to form deoxythymidine monophosphate (dTMP) and dihydrofolate
(H2folate). The essential role of TS in the cell life cycle makes it an attractive target
for the development of substrate and cofactor-based inhibitors that may find efficacy
as anticancer and antiproliferative drugs. Antifolates that compete specifically with
the binding of CH2H4 folate include the cofactor analog CB3717 (10-propargyl-5,8-
dideazafolate). However, the development of potent cofactor analog inhibitors of TS,
such as CB3717, as drugs has been slowed by their toxicity, which often becomes
apparent as hepatic and renal toxicity mediated by the specific chemistry of the
compound. Attempts to abolish toxicity in human patients while preserving potency
against the target enzyme, have led to the development of ZD1694, which has
already shown significant activity against colorectal tumours.
Results:  The three dimensional crystallographic structure of ZD1694 in complex
with dUMP and Escherichia coli TS has been determined to a resolution of 2.2Å.
This was used to evaluate the specific structural determinants of ZD1694 potency
and to correlate structure/activity relationships between it and the closely related
ligand, CB3717. ZD1694 binds to TS in the same manner as CB3717 and
H2folate, but a methyl group on its quinazoline ring, its thiophene ring and the
methyl group at N10 are compensated for by plastic accommodation of the enzyme
active site coupled with specific rearrangement in the solvent structure. A specific
hydrogen bond between the protein and the inhibitor CB3717 is absent in the
case of ZD1694 whose monoglutamate tail is reoriented and more well ordered.
Conclusions:  The binding mode of ZD1694 to thymidylate synthase has been
determined at atomic resolution. ZD1694 forms a ternary complex with dUMP and
participates in the multi-step TS reaction through the covalent bond formation
between dUMP and Cys146 thereby competing with CH2H4folate at the active
site. Analysis of this inhibitor ternary complex structure and comparison with that of
CB3717 reveals that the enzyme accommodates the differences between the two
inhibitors with small shifts in the positions of key active site residues and by
repositioning an active site water molecule, thereby preserving a general binding
mode of these inhibitors.
Introduction
Thymidylate synthase (TS; EC 2.1.1.45) is recognized 
and exploited as the target of various anticancer drugs
because it catalyzes the reductive methylation of deoxyuri-
dine monophosphate (dUMP) in the final step in the 
sole de novo pathway for synthesis of deoxythymidine
monophosphate (dTMP) and is therefore an essential
enzyme of DNA synthesis. This unique role makes TS an
ideal candidate for the design of potent inhibitors which
will serve as lead compounds in the development of anti-
cancer drugs. Drugs that compete directly or indirectly
with dUMP binding to TS include the mechanism-based
derivatives of pyrimidines, such as the well known pro-
drug 5-fluorouracil (5FU) [1,2] which ultimately forms a
covalent mechanism-based inhibitory complex with TS.
Antifolates that compete specifically with the binding of
the fully reduced form of folate, CH2H4folate, include the
analog 10-propargyl-5,8-dideazafolate, CB3717, discovered
by Jones and colleagues [3–5]. CB3717, which inhibits
human TS in vitro with Ki ~10nM and displays antitumor
activity in vivo, demonstrates excellent clinical efficacy;
however, CB3717 has a poor therapeutic index due to its
low solubility at urinary and hepatic pH. Clinical trials
were halted after a small proportion of patients exhibited
renal and hepatic toxicity [3–7].
Numerous analogs of the quinazloine-based CB3717 have
been made and screened to characterize those with
improved solubility. A 2-desamino-2-methyl compound,
ZD1694 (sold under the trade name Tomudex) was found
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to have high solubility. Though it has weaker binding 
to free TS (Ki =670nM), it has improved interaction with
the enzyme, folylpolyglutamate synthase (FPGS), that
attaches up to five a- and g-linked glutamates to folates
inside the cell. FPGS-mediated polyglutamylation after
cellular uptake serves to sequester the analog within the
target cell and also improves its potency against free TS
by factors up to >100 [8]. ZD1694 therefore is a much
better in vivo inhibitor of TS than is CB3717. ZD1694 is a
potent inhibitor of L1210 (ascitic murine line) cell growth
and leads to regression and elimination of ascitic tumors in
whole mice [8]. The antitumor activity of ZD1694 is pre-
vented by co-administration of thymidine indicating that
TS is the target of its action in vivo [8]. The antitumor
activity is diminished by co-administration of folinic acid,
but this effect is decreased when folinic acid is given as a
four hour delayed ‘rescue’, indicating that ZD1694 com-
petes with folinic acid for cellular uptake [8]. ZD1694,
approved for human therapy in several European coun-
tries, has recently completed phase III clinical trials and
has shown significant activity against colorectal tumors [9].
ZD1694 differs chemically from its predecessor CB3717 at
three specific sites (Fig. 1). Firstly, the CB3717 quinazo-
line 2-amino group, a hydrogen bond donor, is changed to a
methyl group in ZD1694. This change abolishes intermol-
ecular crosslinking at high pH which presumably prevents
crystallization in the kidney and diminishes the serious
side effect of renal failure. In the complex of Escherichia coli
thymidylate synthase (ECTS) with dUMP and CB3717,
this amino group forms hydrogen bonds to the protein.
Secondly, the p-aminobenzoate (PABA) ring of CB3717 is
changed to a thiophene ring in ZD1694. The most potent
cytotoxic compounds are analogs in which the PABA ring is
replaced by a thiophene ring [10]. The thiophene ring pre-
sumably mediates the improved interaction with FPGS, a
major factor in producing high levels of in vivo potency.
The thiophene and PABA rings are isosteric although the
thiophene ring sulfur confers greater electronegativity to
the ring system. And thirdly, the CB3717 N10-propargyl
substituent is truncated to a methyl group in ZD1694. The
propargyl group confers increased affinity by ~tenfold rela-
tive to CH3 and is essential for potency of CB3717 [6]. Its
role in binding, as seen in the ECTS-dUMP-CB3717 struc-
ture [11], is hydrophobic since the propargyl group extends
into a hydrophobic site and packs against the aromatic ring
of Phe176 and the backbone atoms of Gly173. We have
now determined the structure of ECTS in ternary complex
with dUMP and ZD1694 to investigate how the enzyme
differentially accommodates these fundamental and chem-
ical modifications of the inhibitor, and to define further
sites where subsequent modifications may be focused to
optimize selectivity or affinity. The crystal structure of 
the ECTS-dUMP-ZD1694 complex was determined and
refined to 2.2Å resolution.
Results and discussion
Overall features of the protein and binding
Two molecules of ZD1694 are bound, one in each of two
symmetrically arranged active sites (Figs 2,3). The enzyme
is in the ‘closed’ conformation that is triggered by binding
of both substrate and folate (or a folate analog) to TS
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Figure 1
Chemical structures of (a) CB3717 and
(b) ZD1694 showing key differences between
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[11–14] or by binding of antifolates alone [15,16]. The
‘closed’ conformation differs from the ‘open’ conformation,
observed for unliganded TS [17] by the concerted inward
movement of many secondary structural elements. The
resulting conformational change extends throughout the
entire protein and occurs by segmental accommodation
[11]. This conformational change serves to sequester reac-
tants from bulk solvent and to position the substrate and
cofactor for catalysis. The structure of the protein compo-
nents of the ZD1694 and CB3717 complexes are very
similar. Least squares superimposition guided by Ca atoms
of the ZD1694 complex and the CB3717 complex resulted
in a root mean square (rms) deviation of 0.19Å on positions
of protein Ca atoms and a rms deviation of 0.75Å on posi-
tions of all protein atoms.
Inhibitor binding at the active site
The bound conformation and orientation of ZD1694 is
essentially the same as observed in TS ternary complexes
with folates [12], or CB3717 [11]. Key interactions between
protein sidechains and CB3717, unless otherwise noted,
are preserved in the ZD1694 structure. The refined omit
difference electron density map calculated after omitting
the catalytic active site residue Cys146, the substrate
dUMP and the inhibitor ZD1694 clearly shows resolved
electron density for every atom excluded (Fig. 4). The sub-
strate dUMP binds at the bottom of the large active site
with the pyrimidine ring in an anti orientation and the
ribose ring in a C2′ endo conformation. A covalent bond,
seen clearly in the difference electron density map, is
formed between the Sg of Cys146 and the C6 position of
the pyrimidine ring. ZD1694 binds adjacent to the sub-
strate, securing the pyrimidine ring of dUMP in its produc-
tive binding to the catalytic nucleophile, Sg of Cys146
(Fig. 5). In the normal course of the catalytic reaction, this
covalent bond activates the C5 position of the pyrimidine
ring for bond formation with the iminium ion methylene
from the CH2H4folate cofactor. In ZD1694, as there is no
reactive methylene to donate, the receptive substrate
intermediate is generated once the Sg–C6 bond is formed
and stabilized by the binding of ZD1694. This arrange-
ment and orientation of substrate and cofactor analog is
also similar in detail to that of the product and oxidized
cofactor bound to an active site mutant of ECTS, in 
the product complex structure [12]. This shows that the
binding of dUMP and ZD1694 to TS causes the normal
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Figure 2
Cross-eyed stereo view of the protein
a carbon trace for a single monomer of the 
TS structure showing the locations of
residues. ZD1694 and substrate dUMP are
also shown as all atom representations in the
active site. (Figure generated using the
program CHAIN [27].)
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Figure 3
Stylized ribbon representation of ZD1694 bound with substrate dUMP
to the TS dimer showing the relative locations of substrate and
inhibitor binding. One inhibitor molecule (ZD1694) and one substrate
molecule (dUMP) bind in each of two, twofold-related active sites. In
each active site, dUMP binds closest to the dimer interface. (Figure
generated using the program MidasPlus [25,26].) 
reaction to proceed as far as the covalent bond formation
between dUMP C6 and the Cys146 Sg, whereupon a cova-
lent inhibitory complex is formed.
Superimposition and comparison of the ECTS-dUMP-
ZD1694 and the ECTS-dUMP-CB3717 structures and the
ECTS-dUMP-CB3717 structure reveals a set of 28
residues in the first monomer (residues 1–264), that differ
in position by more than four times the amount expected
based on the average B factor of the compared atoms [18].
Most of these residues are located on the solvent-accessi-
ble surface of the protein and do not interact with the
bound ligands. Specific residues at the enzyme inhibitor
interface have statistically significant positional shifts.
The residues from both structures within 5.0Å of the
bound inhibitor and the surrounding active site are shown
in Figure 6. In the ECTS-dUMP-ZD1694 structure the
sidechains of Leu172 and Phe176 pack against the thio-
phene ring and have a rms positional shift of 1.9Å and
2.2Å respectively, relative to the ECTS-dUMP-CB3717
structure. The rearrangement of these sidechains accom-
modates the increased steric bulk of the sulfur atom and
the small changes in the position of the thiophene ring 
relative to the PABA ring in the ECTS-dUMP-CB3717
structure. The sidechain of Glu82 lies farther from the
inhibitor making its closest approach, of 6.8 Å, between
Glu82 Oε2 and the carbonyl oxygen of ZD1694 adjacent
to the glutamic acid tail. Nonetheless, the Glu82 sidechain
has a rms shift of 1.9Å relative to the ECTS-dUMP-
CB3717 structure. This rearrangement may be due to
shifts in the position of the glutamic acid tail and bound
water molecules nearby.
The 2-desamino-2-methyl quinazoline ring of the ZD1694
packs against the uridine ring of the substrate dUMP in
the mode observed for the quinazoline ring of  CB3717. In
ZD1694, a methyl group occupies the 2- position of this
ring system. This methyl group is bound in a pocket
formed by side chains of residues Asp169, Tyr209, the car-
bonyl oxygen of Ala263 and a well ordered water mole-
cule, Wat580 . In the ECTS-dUMP-ZD1694 structure the
interatomic distances between the methyl carbon and the
closest atoms of each of these residues ranges from 3.3 to
3.8Å (Table 1). In the ECTS-dUMP-CB3717 structure,
the 2-amino group of CB3717 makes a strong 2.8Å hydro-
gen bond to the carbonyl of the penultimate residue,
Ala263, and much weaker 3.6Å interactions with the Od of
Asp169 and OH group of Tyr209. The 2-amino group is
also coordinated by a well ordered water molecule with 
a hydrogen bond of 3.1Å. The loss of strong electrostatic
interactions at the 2-position and the entropic cost of
packing the hydrophobic methyl group in a polar pocket
may explain the tenfold loss of affinity seen with ZD1694
compared with CB3717, and the structure described here
suggests ways in which higher affinity could be evoked 
1320 Structure 1996, Vol 4 No 11
Figure 4
Cross-eyed stereo view of refined omit
difference electron density map calculated
with terms [(Fo–Fc) acalc] after omitting
Cys146, dUMP (DUM 565) and ZD1694
(D16 566) from one active site and refining
the structure. The final refined model for the
omitted residue and the ligands are
superimposed. The electron density,
contoured at 2.5 s, is strong and continuous
for the covalent bond between Sg of
Cys146 and C6 of dUMP. Under various
refinement schemes in which the van der
Waals interaction energies between
substrate dUMP and protein were omitted,
the unrestrained distance between these two
atoms refines to that of a reasonable
covalent bond (~1.85 Å). Figure generated
using the program CHAIN [27].
Figure 5
Overview of the cofactor analog ZD1694 bound in the active site of
ECTS. The protein backbone is shown as stylized ribbon in cyan.
ZD1694, dUMP and residues lining the active site are shown 
colored by atom type. (Figure generated using the program 
MidasPlus [25,26].)
in subsequent modifications. A similar rearrangement 
in the water structure at this site is seen in an ECTS
mutant where asparagine replaces Asp169 (C Sage and 
RS, unpublished results).
The volume occupied by the extended propargyl sub-
stituent of CB3717 is vacant in the ZD1694 structure, in
which the backbone Ca of Gly173 is 0.9Å closer to the
N10-methyl group of ZD1694. The propargyl group of
CB3717 is responsible for the highest specificity of the
10-substituted quinazoline-based cofactor analogs. In the
ECTS-dUMP-CB3717 structure, the propargyl group
packs against the conserved Phe176 and the linear axis of
the three carbon group points toward the backbone of
Gly173. The triple bonded terminal carbon is 3.3Å from
Nd of Asn 177, 3.3Å from N3 of dUMP and 3.5Å from O4
of dUMP. In the ECTS-dUMP-ZD1694 structure, the N10
methyl group is a   r the negatively charged monoglutamate
tail is a shallow groove carrying a positive electrostatic
surface potential [16]. Key interactions between the
monoglutamate tail and the protein are mediated through a
network of ordered water molecules (Fig. 7). The two
oxygens of the a-carboxylate form hydrogen bonds to three
water molecules which in turn are hydrogen bonded to the
main-chain protein atoms, His51 N and Ile258 O, and to
the side chain atom Lys48 Nz. One Oε atom of the
ZD1694 g-carboxylate group forms a hydrogen bond to Og
of Ser54 and  both oxygen atoms form a bifurcated hydro-
gen bond with Nd of His51. In the ECTS-dUMP-ZD1694
structure the slightly different orientation of substituents
on the five-membered thiophene ring relative to the
six-membered PABA ring causes a shift of 0.3Å in the Ca
atom of the glutamic acid tail.
Comparison to human thymidylate synthase binding
Thymidylate synthase is a highly conserved enzyme with
a high number of conserved residues comprising the
active site [17]. Visual inspection of the active site rela-
tive to the sequence alignment of ECTS and human
thymidylate synthase (HTS) reveals that sequence varia-
tion does occur in proximity to the bound inhibitor, but
the nature of the substitutions are unlikely to affect the
binding mode of ZD1694 in the HTS active site. In the
ECTS-dUMP-ZD1694 structure there are 20 residues
that have at least one atom within 5 Å of the bound
inhibitor. Of these residues, 14 are conserved in the
sequence alignment between ECTS and HTS, and two
are amino acid substitutions to a smaller side chain. The
remaining four amino acid substitutions are to a larger
side chain and could affect the overall binding mode.
These side chain substitutions are His51, Thr78, Ala260
and Val262 in ECTS for Phe, Lys, Met and Met in HTS,
respectively. However, the side chains of His51, Thr78
and Ala260 all lie closest to the glutamate tail of ZD1694
and comprise the shallow groove in which the tail is
bound, a location least likely to affect inhibitor binding.
His51 and Thr78 mediate interactions with the gluta-
mate tail through hydrogen bonds to well ordered
solvent molecules. In contrast, the side chain of Val262
packs against the quinazoline ring of ZD1694 and
although large perturbations in the protein structure of
this region could affect inhibitor binding, the site of this
side chain could be occupied by the bulkier side chain of
methionine.
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Figure 6
Overlap, guided by superposition of protein Ca’s, of ZD1694 and
CB3717. The local environment of the active site and sidechains from
residues within 5 Å of the bound inhibitor are shown, with sidechains
and ligands from the ZD1694 structure colored by atom and those
from the CB3717 structure colored green. (Figure generated using
program MidasPlus [25,26]).
Table 1
Interatomic distances for analogous atoms in ECTS−dUMP−ZD1694 and ECTS−dUMP−CB3717 structures.
CB3717 D (Å) ZD1694 D (Å)
NA2 Asp169 OD2 3.7 CM2 Asp169 OD2 3.8
NA2 Tyr209 OH 3.7 CM2 Tyr209 OH 3.7
NA2 Ala263 O 2.8 CM2 Ala263 O 3.3
NA2 Wat580 O 3.1 CM2 Wat580 O 3.4
N10 Gly173 Ca 6.0 N10 Gly173 Ca 5.4
Biological implications
Thymidylate synthase (TS) catalyzes the committed step
in the sole de novo pathway for biosynthesis of thymidine
and is therefore important for the production of DNA,
but is not required for the synthesis of mRNA. Thus
inhibitors that target TS, act preferentially on cells that
are rapidly proliferating with an elevated demand for
DNA synthesis, such as cancer cells. In a well studied,
multi-step mechanism [19,20] TS catalyzes the reductive
methylation of deoxyuridine monophosphate (dUMP) by
transfer and subsequent reduction of a methylene group
from the cofactor methylenetetrahydrofolate (5,10-
CH2THF) to yield deoxythymidine monophosphate
(dTMP) and dihydrofolate (H2folate).
Recently, ZD1694 (trade name Tomudex) has emerged
from phase III clinical trials as a promising and effective
alternative to the only widely approved anticancer
therapy that targets thymidylate synthase, the pro-drug 5-
fluorouracil (5FU) [9]. ZD1694 is less toxic than its pre-
decessor drug candidate, CB3717, which was removed
from clinical trials, despite its effectiveness against TS,
after small numbers of patients developed renal and
hepatic toxicities. ZD1694 is as effective as the approved
combination regime of 5FU and leucovorin (LV) in limit-
ing disease progress and mediating survival [9]. Addition-
ally, patients who received ZD1694 had shorter hospital
stays, higher response rates, reduced toxicity and more
frequent palliative benefits when compared with patients
who received 5-FU plus LV in the treatment of advanced
colorectal cancers [9].
The crystal structure of ZD1694 bound by E. coli TS has
now been determined at a resolution of 2.2Å and used to
evaluate the structural determinants of the ligand–
protein interaction. This structure also provides the
opportunity for comparison of the binding mode of
ZD1694 with that of both the closely related cofactor
analog, CB3717 and the cofactor product, H2folate.
ZD1694 acts as an inhibitor of the multi-step TS reaction
by catalyzing the first part of the reaction, covalent bond
formation between substrate dUMP and the catalytic
thiol Cys146, thereby competing with cofactor 5,10-
CH2THF at the active site. The enzyme is therefore
‘trapped’ at a reversible step midway along the reaction
pathway, because ZD1694 lacks the iminium ion methyl-
ene substituent required for continuation of the normal
reaction. The chemical structure of ZD1694 differs from
that of CB3717 in three distinct ways, each of which is
compensated for by plastic accommodation of the protein
and rearrangement of the solvent structure, thereby pre-
serving the general binding mode of these inhibitors. The
modification of a key amino group in CB3717 to a
methyl group at the same position in ZD1694 abrogates 
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Figure 7
Schematic diagram of the ligand binding
determinants as displayed by the program
LIGPLOT [28]. The hydrogen bond network of
ordered water molecules around the glutamate
tail of ZD1694 is illustrated. The bonds of
ZD1694 are colored purple and those of the
protein are colored black. Hydrogen bonds are
black dashes with the bond length noted.
Protein residues and ligand atoms involved in
hydrophobic contacts with the ligand are
noted with green eyelashes. 
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a specific hydrogen bond between the inhibitor and an
enzyme-ligated water molecule at the active site. The
loss of this energetically favorable interaction may
account for the 67-fold difference in binding affinities for
the free enzyme. The p-aminobenzoate (PABA) moiety
of CB3717 is changed to a thiophene ring in ZD1694
thereby improving the metabolically important interac-
tion between ZD1694 and the enzyme which catalyzes
polyglutamylation, folylpolyglutamate synthase (FPGS).
The same hydrophobic sidechains from active site
residues stack against both the PABA and the thiophene
ring systems in much the same manner. The shifts in
these residue positions probably do not represent large
differences in binding affinities of CB3717 and ZD1694.
The propargyl substituent at N10 in CB3717 is trun-
cated to a methyl group in ZD1694. The binding of this
smaller functional group leads to a slight shift of the
protein backbone toward the inhibitor creating a small
cavity unoccupied by either inhibitor atoms or ordered
solvent molecules. This energetically unfavorable cavity
may account for a small portion of the differences in
binding affinities between CB3717 and ZD1694.
Materials and methods
Protein and co-crystallization
The thyA gene in pUC19 was transformed into E. coli X2913. After
induction to 5 to 10 % of the cellular protein, the enzyme was purified as
described [21], stored as an ammonium sulfate precipitate at –80° C
and dialyzed against 20 mM KPO4, pH8.0, 3.8 mM dithiothriotol (DTT),
and 0.05 mM disodium EDTA for crystallization of the inhibited enzyme.
Ternary complex crystals were grown by hanging drop co-crystallization
of TS with the substrate dUMP and ZD1694. A 5.0 ml drop of protein
solution (20 mM KPO4 pH8.0, 1.5 mgml–1 TS, 1.9 mM ZD1694, 5.8 mM
dUMP, 3.8 mM MgCl2, 3.8 mM DTT, 0.05 mM EDTA and 1.25 M
(NH4)2SO4) was equilibrated at 23° C against an excess of precipitant
solution (2.5 M (NH4)2SO4 and 20 mM KPO4 pH8.0). Crystals with
hexagonal rod morphology grew in 2–3 days, reaching a size of
650 mm × 200 mm × 200 mm. Diffraction intensities were collected using
a Siemens X-100 position sensitive area detector system, CuKa
(1.54Å) radiation, frames of width ∆Ω = 0.2° degree and data collection
times of 300 seconds per frame. A single crystal yielded a complete
dataset with a total of 249 261 observations to 2.2 Å. Intensities from
600 frames recorded using two crystal orientations were integrated,
scaled and reduced using the Siemens software in space group P63
with unit cell dimensions a =b=126.8 Å, c =67.56 Å, a = b =90°,
g =120° to give 30 531 unique reflections with an overall Rsym of
10.05% calculated on intensities. Intensities from 600 frames recorded
using two crystal orientations were intergrated, scaled and reduced
using the Siemens software in space group P63 with unit cell dimen-
sions a =b=126.8Å, c =67.56Å, a = b =90°, g =120° to give 30 531
unique reflections with an overall Rsym of 10.05 % calculated on intensi-
ties (Table 2).
Structure solution and refinement 
The structure was solved by isomorphous molecular replacement using
the reported ECTS-dUMP-CB3717 ternary complex structure [11],
with the ligands and water molecules omitted, as a model. Rigid body
least squares minimization of the model position using X-PLOR [22]
gave an R factor of 29.2 % using all data between 7.0 Å and 2.2 Å. 
A difference electron density map ((Fo–Fc)ac) calculated using the
rigid-body refined model displayed clear, detailed density for the
ligands, ZD1694 and dUMP, and for well ordered solvent molecules.
The ligands were modeled into the difference electron density using
FRODO [23]. The complete model was subjected to alternating cycles
of positional and B factor refinement, including two rounds of simulated
annealing [24] and hand rebuilding. The final R factor is 17.1 % for all
data between 7.0 Å and 2.2 Å for a model with a total of 4649 atoms,
including 245 water molecules. A summary of the data processing and
refinement statistics is presented in Table 2.
ECTS-dUMP-ZD1694 was superimposed on ECTS-dUMP-CB3717 by
automated selection of a core of Ca atoms in the dimer based on differ-
ence distance matrices [17] and minimizing the rms deviation in these
Ca positions in the two structures, using the programs NEWDOME and
GEM [12]. The ECTS-dUMP-ZD1694 structure was compared to the
ECTS-dUMP-CB3717 structure by first deriving an estimate of uncer-
tainty in position expressed as the expectation in standard deviation,
sxyz(B), for each atom in both structures as a function of the averaged B
factor of the compared atoms. The calculated sxyz (B), resolution and
other determinants of the analysis are based on comparison of indepen-
dently determined structures of proteins seen where there are multiple
copies located at different positions in the same crystal [18].
Accession numbers
Coordinates have been deposited with the Protein Data Bank.
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Table 2
Crystallographic data and refinement statistics for the ECTS−dUMP−ZD1694 complex
Resolution (Å)
∞–3.81 3.81–3.02 3.02–2.64 2.64–2.40 2.40–2.20
Crystallographic data
Rsym (I) (%)* 5.55 11.0 21.7 32.8 35.1
Av. I/sig(I) 21.3 7.49 3.32 2.06 1.56
No. of unique reflections, possible 2139 2109 2096 2089 2109
No. of reflections, collected 6218 6106 6094 6066 6047
No. of observations,total 66 227 59 336 50 753 41677 31268
Completeness of data (%) 99.9 99.7 99.8 100.0 99.0
Redundancy 10.7 9.7 8.3 6.9 5.2
Rcryst of refined structure (%)† 12.9 14.1 18.7 21.1 26.4
(7.0–4.0 Å)
*Rsym = (ΣhklΣΝi=l[Iavg–Ii]2 / [ΣhklΣΝi=l(Ii)2])½. †Rcryst = Σ|(|Fo|–|Fc|)| / Σ|Fo|.
Rms deviations from ideality in final model were: 0.014 Å (Bond
lengths); 3.53° (Bond angles); 22.5° (Dihedral angles) and 3.91°
(Improper angles). Improper angles define chiral centres and planar
groups of atoms. 
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